- Home
- RDHL vs BFRI Comparison
RDHL vs BFRI Comparison
Compare RDHL & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- BFRI
- Stock Information
- Founded
- RDHL 2009
- BFRI 1997
- Country
- RDHL Israel
- BFRI United States
- Employees
- RDHL N/A
- BFRI N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- BFRI Health Care
- Exchange
- RDHL Nasdaq
- BFRI Nasdaq
- Market Cap
- RDHL 7.5M
- BFRI 6.2M
- IPO Year
- RDHL N/A
- BFRI 2021
- Fundamental
- Price
- RDHL $5.64
- BFRI $1.10
- Analyst Decision
- RDHL
- BFRI Strong Buy
- Analyst Count
- RDHL 0
- BFRI 1
- Target Price
- RDHL N/A
- BFRI $7.00
- AVG Volume (30 Days)
- RDHL 13.8K
- BFRI 960.5K
- Earning Date
- RDHL 08-29-2024
- BFRI 03-14-2025
- Dividend Yield
- RDHL N/A
- BFRI N/A
- EPS Growth
- RDHL N/A
- BFRI N/A
- EPS
- RDHL N/A
- BFRI N/A
- Revenue
- RDHL $3,707,000.00
- BFRI $35,358,000.00
- Revenue This Year
- RDHL $224.90
- BFRI $17.69
- Revenue Next Year
- RDHL $82.69
- BFRI $19.71
- P/E Ratio
- RDHL N/A
- BFRI N/A
- Revenue Growth
- RDHL N/A
- BFRI 5.17
- 52 Week Low
- RDHL $5.41
- BFRI $0.61
- 52 Week High
- RDHL $31.50
- BFRI $2.43
- Technical
- Relative Strength Index (RSI)
- RDHL 35.38
- BFRI 53.42
- Support Level
- RDHL $5.41
- BFRI $0.97
- Resistance Level
- RDHL $5.79
- BFRI $1.11
- Average True Range (ATR)
- RDHL 0.31
- BFRI 0.16
- MACD
- RDHL -0.05
- BFRI -0.01
- Stochastic Oscillator
- RDHL 14.26
- BFRI 15.38
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.